When was Cue Biopharma founded?

Cue Biopharma was founded in 2015 and raised its 1st funding round within a year of its incorporation.

Where is Cue Biopharma located?

Cue Biopharma is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts.

How many employees does Cue Biopharma have?

As of Jul 31, 2026, the latest employee count at Cue Biopharma is 41.

Is Cue Biopharma a funded company?

Cue Biopharma is a funded company, having raised a total of $26.4M across 5 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jun 15, 2015.

When was the latest funding round of Cue Biopharma?

Cue Biopharma's latest funding was a $***** Post IPO round on Jul 13, 2026, with participation from 0 investor.

What is the annual revenue of Cue Biopharma?

Annual revenue of Cue Biopharma is between $10M and $50M as on Dec 31, 2025

Where does Cue Biopharma rank among its competitors?

Cue Biopharma ranks 95th amongst 3453 active competitors, of which 1187 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Cue Biopharma?

Cue Biopharma's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Among them, Cue Biopharma secured the most recent funding round in July, 2026.

Cue Biopharma - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Precision immunotherapies to transform patients' lives by selectively modulating the immune system. It is a biotechnology company engineering biologics designed to selectively engage and modulate targeted T cells. The company focuses on autoimmune diseases and cancer, aiming to restore immune balance. Their proprietary Immuno-STAT platform enhances a patient’s immune system to potentially restore health. They are developing a novel class of therapeutic biologics. The company's approach involves precision medicine, clinical development, and translational research. They are working towards establishing a new standard of care for diseases that cause human suffering and mortality. They are mobilizing the patient’s immune system to treat serious diseases.

Website: www.cuebiopharma.com/
Social
Registered Address: Cambridge, Massachusetts

Key Metrics

Founded Year

2015

Location

Cambridge, United States

Stage

Public

Total Funding

$26.4M in 5 rounds

Latest Funding Round

Post IPO, Jul 13, 2026, $*****

Investors

MDB Capital

Ranked

95^th among 3453 active competitors

Annual Revenue

$10M - $50M as on Dec 31, 2025

Employee Count

41 as on Jul 31, 2026

Similar Companies

Sana Biotechnology & 535 more

Exit Details

Public

View Cue Biopharma's full profile

Cue Biopharma is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
CUE BIOPHARMA INC CIN: 473324577 , United States, Active	Dec 26, 999	-	38 (As on Dec 31, 2024)	-
Cue Biopharma, Inc. CIN: 1645460 , United States, Active	Dec 30, 2014	$10M - $50M (As on Dec 31, 2025)	-	-

Cue Biopharma got listed on Jan 02, 2018.

Click here to take a look at Cue Biopharma's IPO in detail

Cue Biopharma has raised a total funding of $26.4M over 5 rounds. Its first funding round was on Jun 15, 2015. Cue Biopharma has 1 institutional investor.

Here is the list of recent funding rounds of Cue Biopharma:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 13, 2026	6164536	Post IPO	2165134	4333878	5892560	7551513
May 04, 2026	9271636	Post IPO	2207336	9170205	7235783	1344939
Nov 21, 2022	6587678	Post IPO	2484020	3073527	5566714	2477056

Access funding benchmarks and valuations. Sign up today!

View details of Cue Biopharma's funding rounds and investors

The founders of Cue Biopharma is Ron Seidel.

Here are the details of Cue Biopharma's key team members:

Ron Seidel: Co-Founder of Cue Biopharma.

View details of Cue Biopharma's Founder profiles and Board Members

Cue Biopharma's employee count trend

Cue Biopharma has 41 employees as of Jul 26. Here is Cue Biopharma's employee count trend over the years:

Uncover Cue Biopharma's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Cue Biopharma include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Here is the list of Top 10 competitors of Cue Biopharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Google Ventures, Baillie Gifford & 17 others	75/100
3rd	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	72/100
5th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
6th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
7th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	True North, Khosla Ventures & 23 others	71/100
95th	Cue Biopharma 2015, Cambridge (United States), Public	Precision immunotherapies to transform patients' lives by selectively modulating the immune system	$26.4M	MDB Capital	64/100